Biomanufacturing, from Bust to Boom ... to bubble ?  

Oleh:

Thiel, Karl A.

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: Nature Biotechnology: The Science and Business of Biotechnology vol. 22 no. 11 (Nov. 2004), page 1365-1372.
Topik: MANUFACTURING; biomanufacturing

Ketersediaan

Perpustakaan Pusat (Semanggi) Nomor Panggil: NN9.3 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Has a worldwide shortage in biomanufacturing capacity turned to a glut in just 4 years ? A building boom and advances in technology threaten to detail adoption of potentially cheaper transgenic manufacturing platforms. Just 4 years ago, it was common wisdom that the biopharmaceutical industry was facing a wordwide shortage of manufacturing capacity. The poster child for the crisis was enbrel (etanercept), a recombinant solube receptor for tumor necrosis factor developed by immunex (seattle, WA, USA, subsequently acquired by amgen, thousand oaks, CA), and first approved to treat rheumatoid arthritis in November 1998...

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali